Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
The therapeutic potency of exogenous administration of adrenomedullin-2 in ocular neovascular diseases
Author Affiliations & Notes
  • Shinji Kakihara
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Masaaki Tanaka
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Kazutaka Hirabayashi
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Akira Imai
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Yuichi Toriyama
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Yasuhiro Iesato
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Takayuki Sakurai
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Akiko Kamiyoshi
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Hisaka Kawate
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Yuka Ichikawa-Shindo
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Megumu Tanaka
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Kun Dai
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Nanqi Cui
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Yangxuan Wei
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Toshinori Murata
    Ophthalmology, Shinshu University, Matsumoto, Nagano, Japan
  • Takayuki Shindo
    Cardiovascular Research, Shinshu University, Matsumoto, Nagano, Japan
  • Footnotes
    Commercial Relationships   Shinji Kakihara, None; Masaaki Tanaka, None; Kazutaka Hirabayashi, None; Akira Imai, None; Yuichi Toriyama, None; Yasuhiro Iesato, None; Takayuki Sakurai, None; Akiko Kamiyoshi, None; Hisaka Kawate, None; Yuka Ichikawa-Shindo, None; Megumu Tanaka, None; Kun Dai, None; Nanqi Cui, None; Yangxuan Wei, None; Toshinori Murata, None; Takayuki Shindo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4937. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shinji Kakihara, Masaaki Tanaka, Kazutaka Hirabayashi, Akira Imai, Yuichi Toriyama, Yasuhiro Iesato, Takayuki Sakurai, Akiko Kamiyoshi, Hisaka Kawate, Yuka Ichikawa-Shindo, Megumu Tanaka, Kun Dai, Nanqi Cui, Yangxuan Wei, Toshinori Murata, Takayuki Shindo; The therapeutic potency of exogenous administration of adrenomedullin-2 in ocular neovascular diseases. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4937.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Adrenomedullin-2 (AM2) or intermedin, a family peptide of adrenomedullin (AM), is a novel peptide exerting a variety of biological effects, especially regulation of cardiovascular homeostasis. AM and AM2 partially share the receptor system, but functional differentiation is not well understood. Recently, protective effects of endogenous AM2 against various diseases are reported. However, little is known about the pathophysiological roles of AM2 in ocular diseases. In the current study, we analyzed the pathophysiological roles of AM2 in ocular neovascularization by exogenous AM2 administration.

Methods : C57BL/6J mice were subjected to laser-induced choroidal neovascularization (LI-CNV) model and oxygen-induced retinopathy (OIR) model.
In LI-CNV model, 9-12 week-old male mice were treated with intravitreal injection (iv) of 1.5μl PBS, AM (10-7M) or AM2 (10-7M) after CNV induction. After 7 days of CNV induction, CNV size was evaluated by perfused fluorescein-labeled dextran, and macrophage infiltration and fibrosis were evaluated by immunostaining of F4/80 and αSMA, respectively.
In OIR model, both genders of mice were subjected to hyperoxia at 75% oxygen for 5 days from postnatal day (P)7 through P12. P12 mice were treated with iv of 1.5μl PBS, AM (10-7M) or AM2 (10-7M). At P17, avascular area and neovascular tuft area (NVT) were quantified in retinal flatmounts stained with isolectin B4.
In vitro, cell migration of TR-iBRB, a rat retinal endothelial cell line, was evaluated by scratch assay with PBS, AM (10-7M) or AM2 (10-7M). The cell migration distances 12 hours after scratch were evaluated.

Results : In LI-CNV model, CNV size, F4/80-positive cells and αSMA-positive area were significantly reduced by AM or AM2 iv compared to PBS iv(p<0.05).
In OIR model, avascular area was significantly reduced by AM or AM2 iv compared to PBS iv(p<0.01). On the other hand, there was no significant difference in NVT between AM2 iv and PBS iv. NVT was significantly increased by AM iv compared to PBS or AM2 iv(p<0.05).
Addition of AM or AM2 significantly accelerated TR-iBRB cell migration compared to that of PBS(p<0.05).

Conclusions : These results suggest AM2 is expected as a novel therapeutic target of ocular neovascular diseases.

This is a 2020 ARVO Annual Meeting abstract.

 

LI-CNV was improved by AM or AM2 iv compared to PBS iv.

LI-CNV was improved by AM or AM2 iv compared to PBS iv.

 

OIR model: Avascular area was reduced by AM or AM2 iv compared to PBS iv. NVT was deteriorated by AM iv compared to PBS or AM2 iv.

OIR model: Avascular area was reduced by AM or AM2 iv compared to PBS iv. NVT was deteriorated by AM iv compared to PBS or AM2 iv.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×